Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Protara Therapeutics, Inc.
Report date September 14, 2020 · Filed September 15, 2020
Section 16 reporting ended · disclosed 2020-09-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 585,600 |
Ending reported balance
After 2020-09-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-09-14 · Sale · Disposed 2,080 · Balance 586,074 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.50, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Row 2 · 2020-09-14 · Sale · Disposed 474 · Balance 585,600 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.50, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2020 Filed Sep 15, 2020 18:04 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 474 | $20.00 | $9,480.00 |
DisclosureSEC source: 0001179110-20-009785 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,600 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 18:04 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,080 | $19.26 | $40,060.80 |
DisclosureSEC source: 0001179110-20-009785 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,074 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.50, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 16:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 239 | $18.00 | $4,302.00 |
DisclosureSEC source: 0001179110-20-009717 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,154 Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 15:58 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 4,913 | $19.27 | $94,673.51 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,393 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.02 to $19.715, inclusive. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 15:58 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 5,309 | $18.10 | $96,092.90 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,306 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.82, inclusive. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 15:58 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 3,108 | $18.94 | $58,865.52 |
DisclosureSEC source: 0001179110-20-009662 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,615 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.29, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 16:39 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 52 | $20.19 | $1,049.88 |
DisclosureSEC source: 0001179110-20-009590 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,723 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.20, inclusive. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 16:39 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 207 | $20.68 | $4,280.76 |
DisclosureSEC source: 0001179110-20-009590 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,775 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.21 to $20.80, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 16:53 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 771 | $22.09 | $17,031.39 |
DisclosureSEC source: 0001179110-20-009466 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,982 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.475, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 15:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 616 | $22.37 | $13,779.92 |
DisclosureSEC source: 0001179110-20-009407 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,753 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.08 to $23.005, inclusive. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 15:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,418 | $22.40 | $31,763.20 |
DisclosureSEC source: 0001179110-20-009407 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,369 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.03, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 16:27 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,461 | $22.73 | $55,938.53 |
DisclosureSEC source: 0001179110-20-009359 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,787 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.10, inclusive. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 16:27 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 974 | $23.16 | $22,557.84 |
DisclosureSEC source: 0001179110-20-009359 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,248 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.09 to $23.29, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 09:51 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 510 | $24.18 | $12,333.33 |
DisclosureSEC source: 0001179110-20-009241 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,222 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.515, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 200 | $25.19 | $5,038.00 |
DisclosureSEC source: 0001179110-20-009191 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,732 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.11 to $25.28, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 17:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,548 | $25.11 | $38,870.28 |
DisclosureSEC source: 0001179110-20-009153 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,932 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.55, inclusive. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 700 | $25.09 | $17,563.00 |
DisclosureSEC source: 0001179110-20-009153 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,480 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.32, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 16:59 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,317 | $26.14 | $34,426.38 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 4 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,180 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.525, inclusive. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 100 | $28.45 | $2,845.00 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,497 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 600 | $27.28 | $16,368.00 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,597 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.83, inclusive. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:59 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,816 | $26.03 | $47,270.48 |
DisclosureSEC source: 0001179110-20-008623 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,197 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.35, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 600 | $35.45 | $21,270.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 8 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,013 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.00, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,650 | $33.79 | $55,753.50 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 7 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,613 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.34, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,200 | $33.09 | $39,708.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 6 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,263 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.60 to $33.34, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 3,493 | $31.53 | $110,134.29 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 5 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,463 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $32.01, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 14,243 | $30.42 | $433,272.06 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 4 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,956 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $31.00, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,811 | $28.63 | $51,848.93 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,199 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.41, inclusive. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,600 | $26.85 | $69,810.00 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,010 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.38 to $27.38, inclusive. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 338 | $26.08 | $8,815.04 |
DisclosureSEC source: 0001179110-20-008539 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,610 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.06 to $26.24, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (8) to this Form 4. Read SEC document |
| July 24, 2020 Filed Jul 27, 2020 16:07 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 300 | $26.00 | $7,800.00 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,948 Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:07 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 93 | $27.29 | $2,537.97 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,248 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 to $27.49, inclusive. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:07 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,950 | $26.58 | $51,831.00 |
DisclosureSEC source: 0001179110-20-008490 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.10, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:31 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 75 | $27.45 | $2,058.38 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,291 Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:31 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,297 | $26.69 | $34,616.93 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,366 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.20, inclusive. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:31 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 223 | $26.56 | $5,922.88 |
DisclosureSEC source: 0001179110-20-008426 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,663 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 and $27.05, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 16:44 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 472 | $27.68 | $13,064.96 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 3 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,886 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $28.11, inclusive. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 16:44 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,257 | $26.70 | $60,261.90 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,358 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.375 to $27.10, inclusive. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 16:44 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,601 | $26.66 | $42,682.66 |
DisclosureSEC source: 0001179110-20-008399 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,615 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.87, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,145 | $27.13 | $58,193.85 |
DisclosureSEC source: 0001179110-20-008254 · edgar.xml · nonDerivative · entry 2 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,216 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.70, inclusive. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 16:40 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 2,659 | $27.41 | $72,883.19 |
DisclosureSEC source: 0001179110-20-008254 · edgar.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,361 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.01, inclusive. The reporting person undertakes to provide to Protara Therapeutics, Inc., any security holder of Protara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 18:59 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 654,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-003225 · doc4.xml · nonDerivative · entry 1 Marshall Randall · CIK 0001799325 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,020 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F2 · price: These shares were received in exchange for 3,428,572 shares of ArTara Sub Common Stock in connection with the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.